U.S. testosterone shortage: call for information.

Résumé fourni par la source

There is a nationwide shortage of certain injectable testosterone products following FDA actions against Steris Laboratories Inc., a division of Schein Pharmaceuticals, Inc. The FDA seized large stocks of the drugs at Steris Laboratories and shut down manufacturing, alleging that the company had not followed the proper procedures for documenting quality assurance. A "Consent Decree of Condemnation and Permanent Injunction" has allowed the company to resume distribution of some of its products, but this does not include the testosterone products. Steris is the only U.S. manufacturer of some of the testosterone products and is also the supplier for other companies that market these products. Testosterone patches and some other testosterone products are available, but they are more expensive and may not be covered under some managed-care contracts.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.